A potential treatment of nonalcoholic fatty liver disease with SIRT1 activators

Journal of Gastrointestinal and Liver Diseases

Volumn 23, Issue 3, 2014, Pages 311-318

  Colak, Yasar ^a   Yesil, Atakan ^b   Mutlu, Hasan Huseyin ^a   Caklili, Ozge Telci ^a   Ulasoglu, Celal ^a   Takir, Mumtaz ^a   Kostek, Osman ^a   Senates, Ebubekir ^c   Yilmaz, Yusuf ^d   Enc, Feruze Yilmaz ^a   Tasan, Guralp ^a   Tuncer, Ilyas ^a  

^a GOZTEPE TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^c DICLE UNIVERSITY   (Turkey)

^d MARMARA UNIVERSITY   (Turkey)

Author keywords

Nonalcoholic fatty liver disease; Resveratrol; Sirtuin 1; Therapy

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ENZYME ACTIVATOR; SIRT1 PROTEIN, HUMAN; SIRTUIN 1;

ANIMAL; DRUG DESIGN; DRUG EFFECTS; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYMOLOGY; HUMAN; LIVER; METABOLISM; MOLECULARLY TARGETED THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DRUG DESIGN; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVATORS; HUMANS; LIVER; MOLECULAR TARGETED THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; SIRTUIN 1;

EID: 84906880319     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: 10.1543/jgld.2014.1121     Document Type: Review

References (110)

1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55: 2005-2023.
2. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34: 274-285.
3. Lam YY, Peterson CM, Ravussin E. Resveratrol vs. calorie restriction: data from rodents to humans. Exp Gerontol 2013;48: 1018-1024.
4. Silva JP, Wahlestedt C. Role of Sirtuin 1 in metabolic regulation. Drug Discov Today 2010;15: 781-791.
5. Xu Q, Si LY. Resveratrol role in cardiovascular and metabolic health and potential mechanisms of action. Nutr Res 2012;32: 648-658.
6. Colak Y, Ozturk O, Senates E, et al. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit 2011;17: HY5- HY 9.
7. Li L, Hai J, Li Z, et al. Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol 2014;63: 166-173.
8. Castro RE, Ferreira DM, Afonso MB, et al. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol 2013;58: 119-125.
9. Choi Y, Yanagawa Y, Kim S, Park T. Involvement of SIRT1-AMPK signaling in the protective action of indole-3-carbinol against hepatic steatosis in mice fed a high-fat diet. J Nutr Biochem 2013;24: 1393-1400.
10. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002;16: 663-678.
11. Başaranoǧlu M, Ormeci N. Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management. Turk J Gastroenterol 2014;25: 127-132.
12. Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci 2013;14: 20704-20728
13. Knight CM, Gutierrez-Juarez R, Lam TK, et al. Mediobasal hypothalamic SIRT1 is essential for resveratrol's effects on insulin action in rats. Diabetes 2011;60: 2691-2700.
14. Lee JH, Song MY, Song EK, et al. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes 2009;58: 344-351.
15. Yoshizaki T, Milne JC, Imamura T, et al. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol 2009;29: 1363-1374.
16. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschop MH. Sirt1 protects against high-fat diet induced metabolic damage. Proc Natl Acad Sci U S A 2008;105: 9793-9798.
17. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005;434: 113-118.
18. Liu Y, Dentin R, Chen D, et al. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature 2008;456: 269-273.
19. Nie Y, Erion DM, Yuan Z, et al. STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat Cell Biol 2009;11: 492-500.
20. Erion DM, Yonemitsu S, Nie Y, et al. SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats. Proc Natl Acad Sci U S A 2009;106: 11288-11293.
21. Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004;429: 771-776.
22. Chakrabarti P, English T, Karki S, et al. SIRT1 controls lipolysis in adipocytes via FOXO1-mediated expression of ATGL. J Lipid Res 2011;52: 1693-1701.
23. Bai L, Pang WJ, Yang YJ, Yang GS. Modulation of Sirt1 by resveratrol and nicotinamide alters proliferation and differentiation of pig preadipocytes. Mol Cell Biochem 2008;307: 129-140.
24. Gillum MP, Kotas ME, Erion DM, et al. SirT1 regulates adipose tissue inflammation. Diabetes 2011;60: 3235-3245.
25. Amat R, Planavila A, Chen SL, Iglesias R, Giralt M, Villarroya F. SIRT1 controls the transcription of the peroxisome proliferator-activated receptor-gamma co-activator-1alpha (PGC-1alpha) gene in skeletal muscle through the PGC-1alpha autoregulatory loop and interaction with MyoD. J Biol Chem 2009;284: 21872-21880.
26. Gerhart-Hines Z, Rodgers JT, Bare O, et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J 2007;26: 1913-1923.
27. Nogueiras R, Habegger KM, Chaudhary N, et al. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev 2012;92: 1479-1514.
28. Amat R, Solanes G, Giralt M, Villarroya F. SIRT1 is involved in glucocorticoid-mediated control of uncoupling protein-3 gene transcription. J Biol Chem 2007;282: 34066-34076.
29. Nguyen P, Leray V, Diez M, et al. Liver lipid metabolism. J Anim Physiol Anim Nutr (Berl) 2008;92: 272-283.
30. Zhao C, Dahlman-Wright K. Liver X receptor in cholesterol metabolism. J Endocrinol 2010;204: 233-240.
31. Ducheix S, Lobaccaro JM, Martin PG, et al. Liver X Receptor: an oxysterol sensor and a major player in the control of lipogenesis. Chem Phys Lipids 2011;164: 500-514.
32. Wójcicka G, Jamroz-Wiśniewska A, Horoszewicz K, Bełtowski J. Liver X receptors (LXRs). Part I: structure, function, regulation of activity, androle in lipid metabolism. Postepy Hig Med Dosw (Online) 2007;61: 736-759.
33. Ducheix S, Montagner A, Theodorou V, Ferrier L, Guillou H. The liver X receptor: a master regulator of the gut-liver axis and a target for non alcoholic fatty liver disease. Biochem Pharmacol 2013;86: 96-105.
34. Fiévet C, Staels B. Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis. Biochem Pharmacol 2009;77: 1316-1327.
35. Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell 2007;28: 91-106.
36. Eberlé D, Hegarty B, Bossard P, Ferré P, Foufelle F. SREBP transcription factors: Master regulators of lipid homeostasis. Biochimie 2004;86: 839-848
37. Ponugoti B, Kim DH, Xiao Z, et al. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J Biol Chem 2010;285: 33959-33970.
38. Walker AK, Yang F, Jiang K, et al. Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev 2010;24: 1403-1417.
39. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 2009;9: 327-338.
40. Hori YS, Kuno A, Hosoda R, Horio Y. Regulation of FOXOs and p53 by SIRT1 Modulators under Oxidative Stress. PLOS ONE 2013;8: e73875.
41. Hwang JW, Yao H, Caito S, Sundar IK, Rahman I. Redox regulation of SIRT1 in inflammation and cellular senescence. Free Radic Biol Med 2013;61C: 95-110.
42. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012;52: 59-69.
43. Konstantinidis K, Whelan RS, Kitsis RN. Mechanisms of cell death in heart disease. Arterioscler Thromb Vasc Biol 2012;32: 1552-1562.
44. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 2000;1: 120-129.
45. Horio Y, Hayashi T, Kuno A, Kunimoto R. Cellular and molecular effects of sirtuins in health and disease. Clin Sci (Lond) 2011;121: 191-203.
46. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001;107: 137-148.
47. van Leeuwen I, Lain S. Sirtuins and p53. Adv Cancer Res 2009;102: 171-195.
48. Lin Z, Fang D. The roles of SIRT1 in cancer. Genes Cancer 2013;4: 97-104.
49. Nakata R, Takahashi S, Inoue H. Recent advances in the study on resveratrol. Biol Pharm Bull 2012;35: 273-279.
50. Carrizzo A, Forte M, Damato A, et al. Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food Chem Toxicol 2013;61: 215-226.
51. Ghanim H, Sia CL, Abuaysheh S, et al. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab 2010;95: E1-E8.
52. Ghanim H, Sia CL, Korzeniewski K, et al. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J Clin Endocrinol Metab 2011;96: 1409-1414.
53. Timmers S, Konings E, Bilet L et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011;14: 612-622.
54. Brasnyó P, Molnár GA, Mohás M, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 2011;106: 383-389.
55. Bo S, Ciccone G, Castiglione A, et al. Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr Med Chem 2013;20: 1323-1331.
56. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005;11: 183-190.
57. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431: 461-466.
58. Day CP. From fat to inflammation. Gastroenterology 2006;130: 207-210.
59. Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaBdependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004;23: 2369-2380.
60. Schug TT, Xu Q, Gao H, et al. Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress. Mol Cell Biol 2010;30: 4712-4721.
61. Sparks LM, Xie H, Koza RA, et al. A high-fat diet coordinately downregulates genes required for mitochondrial oxidative phosphorylation in skeletal muscle. Diabetes 2005;54: 1926-1933.
62. Scarpulla RC. Nuclear activators and coactivators in mammalian mitochondrial biogenesis. Biochim Biophys Acta 2002;1576 1-14.
63. Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004;117: 5965-5973.
64. Zhang R, Chen HZ, Liu JJ, et al. SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages. J Biol Chem 2010;285: 7097-7110.
65. Xu F, Gao Z, Zhang J, et al. Lack of SIRT1 (Mammalian Sirtuin 1) activity leads to liver steatosis in the SIRT1+/-mice: A role of lipid mobilization and inflammation. Endocrinology 2010;151: 2504-2514.
66. Colak Y, Senates E, Yesil A, et al. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine 2013;43: 100-107.
67. Oni ET, Agatston AS, Blaha MJ, et al. A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; Should we care? Atherosclerosis 2013;230: 258-267.
68. Kocabay G, Karabay CY, Colak Y, et al. Left atrial deformation parameters in patients with non-alcoholic fatty liver disease: A 2D speckle tracking imaging study. Clin Sci (Lond) 2014;126: 297-304.
69. Karabay CY, Kocabay G, Kalayci A, et al. Impaired left ventricular mechanics in nonalcoholic fatty liver disease: a speckle-tracking echocardiography study. Eur J Gastroenterol Hepatol 2013;26: 325-331.
70. Colak Y, Karabay CY, Tuncer I, et al. Relation of epicardial adipose tissue and carotid intima-media thickness in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2012;24: 613-618.
71. Chong ZZ, Wang S, Shang YC, Maiese K. Targeting cardiovascular disease with novel SIRT1 pathways. Future Cardiol 2012;8: 89-100.
72. Stein S, Matter CM. Protective roles of SIRT1 in atherosclerosis. Cell Cycle 2011;10: 640-664.
73. Mattagajasingh I, Kim CS, Naqvi A, et al. SIRT1 promotes endotheliumdependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 2007;104: 14855-14860.
74. Zhang QJ, Wang Z, Chen HZ, et al. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res 2008;80: 191-199.
75. Miyazaki R, Ichiki T, Hashimoto T, et al. SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008;28: 1263-1269.
76. Stein S, Lohmann C, Schafer N, et al. SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J 2010;31: 2301-2309.
77. Potente M, Ghaeni L, Baldessari D, et al. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev 2007;21: 2644-2658.
78. Hsu CP, Zhai P, Yamamoto T, et al. Silent information regulator 1 protects the heart from ischemia/reperfusion. Circulation 2010;122: 2170-2182.
79. Hung LM, Su MJ, Chen JK. Resveratrol protects myocardial ischemiareperfusion injury through both NO-dependent and NO-independent mechanisms. Free Radic Biol Med 2004;36: 774-781.
80. Liu K, Czaja MJ. Regulation of lipid stores and metabolism by lipophagy. Cell Death Differ 2013;20: 3-11.
81. Lekli I, Ray D, Mukherjee S, et al. Co-ordinated autophagy with resveratrol and γ-tocotrienol confers synergetic cardioprotection. J Cell Mol Med 2010;14: 2506-2518.
82. Gurusamy N, Lekli I, Mukherjee S, et al. Cardioprotection by resveratrol: A novel mechanism via autophagy involving the mTORC2 pathway. Cardiovasc Res 2010;86: 103-112.
83. Usta E, Mustafi M, Walker T, Ziemer G. Resveratrol suppresses apoptosis in intact human cardiac tissue -in vitro model simulating extracorporeal circulation. J Cardiovasc Surg 2011;52: 399-409.
84. Raynes R, Brunquell J, Westerheide SD. Stress inducibility of SIRT1 and its role in cytoprotection and cancer. Genes Cancer 2013;4: 172-182.
85. Tang BL. Sirt1's systemic protective roles and its promise as a target in antiaging medicine. Transl Res 2011;157: 276-284.
86. Ota H, Eto M, Ako J, et al. Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: Therapeutic implication of cilostazol after drug-eluting stent implantation. J Am Coll Cardiol 2009;53: 2298-2305.
87. Ota H, Akishita M, Eto M, Iijima K, Kaneki M, Ouchi Y. Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J Mol Cell Cardiol 2007;43: 571-579.
88. Ota H, Eto M, Kano MR, et al. Cilostazol inhibits oxidative stressinduced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler Thromb Vasc Biol 2008;28: 1634-1639.
89. Zu Y, Liu L, Lee MY, et al. SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells. Circ Res 2010;106: 1384-1393.
90. Hou X, Xu S, Maitland-Toolan KA, et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 2008;283: 20015-20026.
91. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 1999;277: E1-E10.
92. Ouchi N, Shibata R, Walsh K. AMP-activated protein kinase signaling stimulates VEGF expression and angiogenesis in skeletal muscle. Circ Res 2005;96: 838-846.
93. Orimo M, Minamino T, Miyauchi H, et al. Protective role of SIRT1 in diabetic vascular dysfunction. Arterioscler Thromb Vasc Biol 2009;29: 889-894.
94. Camins A, Sureda FX, Junyent F, et al. Sirtuin activators: Designing molecules to extend life span. Biochim Biophys Acta 2010;1799: 740-749.
95. Welzel TM, Graubard BI, Quraishi S, et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol 2013;108: 1314-1321.
96. Yilmaz Y, Colak Y, Kurt R, Senates E, Eren F. Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back. Tumori 2013;99: 10-16.
97. Herranz D, Muñoz-Martin M, Cañamero M, et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun 2010;1: 3.
98. Tian Y, Wong VW, Chan HL, Cheng AS. Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. Semin Cancer Biol 2013;23: 471-482.
99. Wang RH, Sengupta K, Li C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008;14: 312-323.
100. Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008;47: 1947-1954.
101. Venkatasubramanian S, Noh RM, Daga S, et al. Cardiovascular effects of a novel SIRT1 activator, SRT2104, in otherwise healthy cigarette smokers. J Am Heart Assoc 2013;2: e000042.
102. Hoffmann E, Wald J, Lavu S, et al. Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. Br J Clin Pharmacol 2013;75: 186-196.
103. Amiot MJ, Romier B, Dao TM, et al. Optimization of trans-Resveratrol bioavailability for human therapy. Biochimie 2013;95: 1233-1238.
104. Libri V, Brown AP, Gambarota G, et al. A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS One 2012;7: e51395.
105. Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011;14: 612-622.
106. Ghanim H, Sia CL, Abuaysheh S, et al. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab 2010;95: E1-E8.
107. Poulsen MM, Vestergaard PF, Clasen BF, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013;62: 1186-1195.
108. Yoshino J, Conte C, Fontana L, et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab 2012;16: 658-664.
109. Chachay VS, Macdonald GA, Martin JH, et al. Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2014 Feb 25.
110. Santos JA, de Carvaho GS, Oliveira V, Raposo NR, da Silva AD. Resveratrol and analogues: a review of antioxidant activity and applications to human health. Recent Pat Food Nutr Agric 2013;5: 144-153